Properties of fujicalin, a new modified anhydrous dibasic calcium phosphate for direct compression: comparison with

H Schlack1, A Bauer-Brandl, R Schubert

  • 1Universität Freiburg, Pharmazeutische Technologie, Germany. Holger.Schlack@Pfizer.com

Related Concept Videos

Portland Cement01:21

Portland Cement

Portland cement is the essential binding ingredient in concrete, made from finely ground materials including lime, iron, silica, and alumina. Lime is derived primarily from limestone, marble, marl, seashells, and clays, which also supply iron and alumina, while silica is sourced from sand, chalk, and bauxite. Contemporary manufacturing of Portland cement is a significant source of carbon dioxide emissions, prompting research into reducing its content in concrete through alternative...
Hydration of Cement01:24

Hydration of Cement

Hydration of cement is a chemical reaction between cement particles and water. This process occurs primarily through two mechanisms: through-solution and topochemical. In the through-solution process, anhydrous compounds dissolve into their constituents, hydrates form in the solution, and then precipitate from the supersaturated solution. The topochemical process involves solid-state reactions at the cement particle surface. The through-solution process dominates the topochemical process at the...
Fineness of Cement01:15

Fineness of Cement

The fineness of cement directly influences the rate of hydration, as the hydration begins at the surface of the cement particles. In addition to hydration, the fineness of cement is vital for various properties of concrete including workability, gypsum requirement, and long-term behavior. The fineness of cement is represented in terms of the specific surface of cement which is typically measured in square meters per kilogram, with several methods available for this determination.
Direct...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...